A.L. Kurenkov, B.I. Bursagova, L.M. Kuzenkova, L.A. Pak, E.V. UvakinaNational Medical Research Center for Children’s Health, Moscow, Russia
The article discusses the issues of diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The emphasis is placed on the clinical and electromyographic criteria for the diagnosis, and the features of the CIDP manifestations in childhood. Pathogenetic methods of treatment – intravenous immunotherapy with standard human immunoglobulin (IVIG), glucocorticosteroid therapy and plasmapheresis – are discussed from the standpoint of evidence-based medicine. The advantages of IVIG (high clinical efficacy, rapid onset of effect, good tolerability, multi-component mechanism of action with multiple points of application, the possibility of carrying out at any age) are emphasized when initiating therapy in children. The use of IVIG with a high 10% concentration of IgG is considered a priority, since it allows to reduce the volume load and provides a significant reduction in the duration of infusion.
For citations: Kurenkov A.L., Bursagova B.I., Kuzenkova L.M., Pak L.A., Uvakina E.V. Chronic inflammatory demyelinating polyneuropathy in childhood: criteria for diagnosis and approaches to pathogenetic treatment. Farmateka. 2019;26(10):21–26. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.10.21-26
Corresponding author: Aleksey L. Kurenkov, MD, Neurologist at the Department of Psychoneurology and Psychosomatic Pathology, Leading Researcher, National Medical Research Center for Children’s Health, Moscow, Russia; e-mail: firstname.lastname@example.org
Address: 2, Build. 1, Lomonosovsky Prospect, Moscow 119991, Russian Federation